[A study of the efficacy of high-dose toremifene in advanced and recurrent breast cancer].
Recently, many patients have been treated with aromatase inhibitors(AI), either in an adjuvant setting or as a treatment for recurrence. The efficacy and safety of high-dose toremifene(HD-TOR)were evaluated in 18 patients with advanced/recurrent breast cancer. Twelve of the 18 patients had received AI just prior to the study treatment. The clinical benefit rate was 56%(PR: 28%, long SD: 28%). Progression-free median survival was 5. 5 months. Adverse events were mild and toremifene was well-tolerated. The results suggest that HD-TOR should be considered early on as a second-line treatment, or as a later treatment option for AI-resistant breast cancer.
Dept. of Surgery, Ashikaga Red Cross Hospital, Japan.
Hideyuki
H
Tokura
Masato
M
Fujisaki
Takayuki
T
Takahashi
Yutaka
Y
Takigawa
Shigeki
S
Onouchi
Kaou
K
Matsuda
Akira
A
Hirata
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012008:Recurrence; D016879:Salvage Therapy; D017312:Toremifene / Q000008:administration & dosage / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D017312:Toremifene